Doxorubicin is a highly effective, first line chemotherapeutic agent used in the management
of hematological and solid tumors. The effective use of doxorubicin in cancer therapy has …

Patients with cancer receiving doxorubicin‑based chemotherapy often have to stop taking
the drug due to its cardiotoxicity and therefore lose out on the beneficial effects of its potent …

Doxorubicin is a widely used and promising anticancer drug; however, a severe dose-
dependent cardiotoxicity hampers its therapeutic value. Doxorubicin may cause acute and …

Doxorubicin (Dox) is a widely administered chemotherapeutic drug and incidences of
cardiotoxicity associated with its administration have been of general concern. Extensive …

Doxorubicin is the mainstay of treatment for various haematological malignancies and solid
tumours. However, its clinical application may be hampered by dose‐dependent …

Although doxorubicin (DOX) is among the most widely used anticancer agents, its clinical
application is hampered owing to its cardiotoxicity. Adjuvant therapy with an antioxidant has …

This study evaluated whether the manipulation of autophagy could attenuate the cardiotoxic
effects of doxorubicin (DXR) in vitro as well as in a tumour-bearing mouse model of acute …

Doxorubicin (Dox) is an effective chemotherapeutic agent used in the treatment of various
cancers. Its clinical use is often limited due to its potentially fatal cardiotoxic side effect …

Doxorubicin (Dox) is an effective chemotherapeutic agent, however, its use is limited by
cardiotoxicity. The mechanisms causing cardiotoxicity have not been clearly elucidated, but …

Background As an anthracycline antibiotic, doxorubicin (DOX) is one of the most potent and
widely used chemotherapeutic agents for various types of solid tumors. Unfortunately …